Juvena is delighted to have had the opportunity to participate in our investor Bison’s AGM. CEO Dr. Yousef was on a panel focused on discussing the latest innovations in AI-driven drug discovery and development
We are thrilled to share that our Director of Discovery and Platform, Thach Mai, PhD, and our Director of Translational Biology, Priya Handa, PhD, represented Juvena Therapeutics at the 16th Drug Discovery Strategic Summit in San Francisco.
CEO, Dr. Hanadie Yousef inspires the next generation of biotech entrepreneurs, in a fireside chat: Targeting the biology of aging to rejuvenate lives- Dr. Yousef’s journey through science research to launching Juvena for the Global Biotech Revolution
Juvena shares updates with the DM community about our muscle regenerating fusion protein, JUV-161 in the “Meet the Myotonic Dystrophy Drug Developers” webinar
CEO Dr. Yousef represents Juvena as a Technology Pioneer at at the World Economic Forum’s Annual Meeting of the New Champions, a.k.a. Summer Davos, in Dalian, China, speaking on “Revolutionary Remedies” and “Letting Biotech Breath”
CEO Dr. Hanadie Yousef gives a talk on Juvena’s AI-enabled protein drug discovery and development platform and lead therapeutic candidates for muscle regeneration and enhancing fat metabolism at the Longevity Summit Dublin
CEO Dr. Hanadie Yousef represents Juvena on 2 panels at BIO San Diego to discuss navigating the frontiers of First-in-Class therapeutics, and how healthspan promoting therapeutics are entering the biopharma mainstream.
Juvena is selected by the World Economic Forum to join its 2024 global cohort of Technology Pioneers, awarded to the 100 most innovative tech startups applying new breakthroughs in AI to solve some of the biggest challenges of our time.
